Development and significance of the plasma cell niche in the human infant thymus

人类婴儿胸腺浆细胞生态位的发育和意义

基本信息

  • 批准号:
    10265678
  • 负责人:
  • 金额:
    $ 39.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-01 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary Our preliminary studies revealed the dynamic evolution of B cell subsets as a function of age in the human thymus. An initial contingent of medullary B cells present at birth and displaying a phenotype of naive B cells is progressively replaced by antigen-experienced, antibody-secreting, class-switched plasma cells confined within the perivascular space (PVS). Plasma cells start to appear in the PVS a few months after birth at a time that is consistent with early exposure to common endemic viruses and vaccination antigens. We propose that this latter subset results from previous immunization and constitute an important pool of memory B cells and plasma cells. The maturing thymus would therefore represent an unrecognized niche for B cell memory alongside the bone marrow. We also hypothesize that thymic resident plasma cells significantly contribute to the humoral immunity through their constitutive antibody-secreting capacity. Our proposed studies will use a large collection of human specimens obtained from donors aged 0-2 years to further characterize this niche during its early development. Using mice immunized with model antigens, we will then investigate mechanisms whereby PC accumulate in the thymus and contribute to the overall serum immunity. Aim 1. To characterize the thymic plasma cell niche in the human infant thymus. We will examine the kinetics of development of the thymic PC niche in ~250 human thymus specimens from donors aged 0-2 years. Using immunochemistry, multicolor flow cytometry, gene expression profiling and next generation sequencing- based IGVH repertoire analysis, we will characterize the architecture, molecular signature and clonal composition of thymic PC in human infants. A comparison with PC subsets in the spleen and bone marrow of the same donors will reveal whether thymic PC have unique features. Aim 2. To determine the reactivity profile of thymic plasma cells in human infants. In aim 2, we will assess the frequency of thymic PC reactive to a broad range of antigens towards which human infants are exposed. These include vaccination viral and bacterial antigens, common food antigens as well as ABO blood group antigens. The possible correlation between antigen-specific B cells in the thymus and the presence of serum IgG specific to the same antigens will be examined. Aim 3. To verify the origin of thymic PC and evaluate their role in serological immunity. Mice immunized with model T cell-dependent and T cell-independent antigens, will be used to verified that thymic PC originate from peripheral immune responses. We will then use a series of genetically-deficient mouse strains to investigate the implication of specific chemokines and chemokine receptors as well as survival factors in the migration and maintenance of thymic PC. Lastly, we will evaluate the capacity of antigen-experienced thymic PC to confer humoral immunity upon adoptive transfer to or transplantation of thymus fragments under the renal capsule of recipient animals.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Emmanuel Zorn其他文献

Emmanuel Zorn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Emmanuel Zorn', 18)}}的其他基金

Source and homeostatic functions of anti-adduct IgM in humans
人类抗加合物 IgM 的来源和稳态功能
  • 批准号:
    10680950
  • 财政年份:
    2023
  • 资助金额:
    $ 39.41万
  • 项目类别:
Thymic plasma cells as a source of protective natural antibodies in human neonates
胸腺浆细胞作为人类新生儿保护性天然抗体的来源
  • 批准号:
    10605000
  • 财政年份:
    2022
  • 资助金额:
    $ 39.41万
  • 项目类别:
Local antibody responses in human cardiac allograft vasculopathy
人心脏同种异体移植血管病中的局部抗体反应
  • 批准号:
    10457560
  • 财政年份:
    2021
  • 资助金额:
    $ 39.41万
  • 项目类别:
Development and significance of the plasma cell niche in the human infant thymus
人类婴儿胸腺浆细胞生态位的发育和意义
  • 批准号:
    9323622
  • 财政年份:
    2017
  • 资助金额:
    $ 39.41万
  • 项目类别:
Development and significance of the plasma cell niche in the human infant thymus
人类婴儿胸腺浆细胞生态位的发育和意义
  • 批准号:
    10204980
  • 财政年份:
    2017
  • 资助金额:
    $ 39.41万
  • 项目类别:
Innate B cell immunity and antibody-mediated rejection of human kidney allografts
先天 B 细胞免疫和抗体介导的人肾同种异体移植排斥
  • 批准号:
    9239152
  • 财政年份:
    2016
  • 资助金额:
    $ 39.41万
  • 项目类别:
Innate B cell immunity and antibody-mediated rejection of human kidney allografts
先天 B 细胞免疫和抗体介导的人肾同种异体移植排斥
  • 批准号:
    9766181
  • 财政年份:
    2016
  • 资助金额:
    $ 39.41万
  • 项目类别:
Contribution of B cells to human cardiac allograft vasculopathy
B 细胞对人心脏同种异体移植血管病的影响
  • 批准号:
    9411075
  • 财政年份:
    2015
  • 资助金额:
    $ 39.41万
  • 项目类别:
Contribution of B cells to human cardiac allograft vasculopathy
B 细胞对人心脏同种异体移植血管病的作用
  • 批准号:
    9114457
  • 财政年份:
    2015
  • 资助金额:
    $ 39.41万
  • 项目类别:
The human innate B cell niche and role in efferocytosis
人类先天 B 细胞生态位及其在胞吞作用中的作用
  • 批准号:
    8875362
  • 财政年份:
    2014
  • 资助金额:
    $ 39.41万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 39.41万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 39.41万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 39.41万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 39.41万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 39.41万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 39.41万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 39.41万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 39.41万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 39.41万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 39.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了